Search

Access

Improving affordable and equal access to innovative therapies in hematology for patients across Europe is EHA’s overriding advocacy priority.

Read more

EHA undersigns Manifesto on Treatment Optimization

EHA has given its formal endorsement to the “Manifesto for a new approach for better medicine in Europe: Establishing Treatment Optimization as part of personalized medicine development”.

Read more

COST Action ‘EuNet-INNOCHRON’

The European Cooperation in Science and Technology (COST) is an EU-funded, intergovernmental framework that aims to create pan-European research networks in all science fields and promote excellence, foster interdisciplinary research and empower young researchers and innovators.

Read more

Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

Read more

Meet Gert Ossenkoppele, our Volunteer of the Month

Can you tell us what you do for EHA and when you started? How did you became a volunteer? Who helped/encouraged you to become one?
I am lucky to be one of the first members of the EHA (member number 34).…

Read more

Meet Gert Ossenkoppele, our Volunteer of the Month

Can you tell us what you do for EHA and when you started? How did you became a volunteer? Who helped/encouraged you to become one?
I am lucky to be one of the first members of the EHA (member number 34).…

Read more